Predictors of Kidney and Patient Survival in Monoclonal Gammopathy–Associated Kidney Disease: A Single-Center Cohort from Colombia
DOI:
https://doi.org/10.61882/ijkd.20.01.8912Keywords:
amyloidosis, multiple mieloma, kidney biopsy, End stage kidney disease, kidney survivalAbstract
Introduction. Monoclonal gammopathies can induce various kidney disorders through the deposition of monoclonal immunoglobulin. Precise recognition and classification are essential for predicting outcomes and customizing treatment. However, data on prognostic factors in Hispanic and Latin American populations remain scarce. This study aimed to determine the predictors of kidney and patient survival in adults with biopsy-proven monoclonal gammopathy-associated kidney disease.
Methods. We conducted a retrospective cohort involving 98 individuals with biopsy-confirmed disease evaluated between 2011 and 2022. Kidney and patient survival were estimated using Kaplan-Meier analysis, and differences across histopathologic subtypes were assessed with the log-rank test. Predictors of end-stage kidney disease (ESKD) and mortality were identified using univariate and multivariable Cox regression after verification of the proportional hazards’ assumption.
Results. Approximately one third of patients required kidney replacement therapy (KRT) at presentation. The need for KRT (hazard ratio [HR] 4.86, 95% confidence interval [CI] 2.01-11.79) and an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² (HR 4.02, 95% CI 1.38-11.71) independently predicted progression to ESKD. Amyloidosis (HR 2.38, 95% CI 1.22-4.86) and age > 60 years (HR 1.96, 95% CI 1.06-3.61) were associated with higher mortality. The median follow-up was 41 months (interquartile range 24-68); 31% progressed to ESKD and 46% died.
Conclusions. Severe kidney dysfunction and the need for replacement therapy at diagnosis are strong predictors of poor renal outcomes. Amyloidosis and older age significantly affect overall survival. Early recognition of high-risk patients and access to effective, clone-directed therapy are essential to improve prognosis in resource-limited settings.
Downloads
References
1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12): e538-48.
2. Leung N, Bridoux F, Nasr SH. Monoclonal gammopathy of renal significance. N Engl J Med. 2021;384(20):1931-41.
3. Netti GS, Troise D, Rossini M, et al. Diagnostic and therapeutic aspects of monoclonal gammopathies of renal significance (MGRS): an update. Diagnostics. 2024;14(28):2892.
4. Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS
is no longer undetermined or insignificant. Blood.
2012;120(22):4292-5.
5. Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance:
a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol. 2019;15(1):45-59.
6. Khera A, Panitsas F, Djebbari F, et al. Long-term outcomes in monoclonal gammopathy of renal significance. Br J Haematol. 2019;186(5):706-16.
7. Alfano G, Delrio A, Fontana F, et al. Clinical presentation, renal histopathological findings, and outcome in patients with monoclonal gammopathy and kidney disease. Int J Nephrol. 2021; 2021:1-9.
8. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362-9.
9. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance
(MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107(3):904-6.
10. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-
term study of prognosis in monoclonal gammopathy
of undetermined significance. N Engl J Med.
2002;346(8):564-9.
11. Klomjit N, Leung N, Fervenza F, Sethi S, Zand L. Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy. J Am Soc Nephrol. 2020;31(10):2400-11.
12. Heilman RL, Velosa JA, Holley KE, Offord KP, Kyle RA. Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis. 1992;20(1):34-41.
13. Tang X, Wan F, Yu J, Li X, Yang R, Zhu B. Clinicopathological characteristics of patients with paraproteinemia and renal damage. Eur J Med Res. 2021;26(1):1-9.
14. Abello V, Mantilla WA, Idrobo H, et al. Real-world evidence of epidemiology and clinical outcomes in multiple myeloma: findings from the Registry of Hemato-Oncologic Malignancies in Colombia. Clin Lymphoma Myeloma Leuk. 2022;22(6): e405-13.
15. Lacouture Fierro JA, Ribero Vargas DA, Sánchez Cano J, et al. Clinical characterization and outcomes of a cohort of Colombian patients with AL amyloidosis. Colomb Med (Cali). 2023;54(3): e2025667.
16. Jairo I, Juliana B, Taborda A, Ospina S, Arias LF. Compromiso renal en gammapatías monoclonales. Rev Esp Patol. 2022;55(1):4-11.
17. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12
18. Barwad A, Bajaj V, Singh G, et al. Monoclonal gammopathy of renal significance: histomorphological spectrum at a tertiary care center. Glomerular Dis.
2022;2(4):153-63.
19. Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol. 2012;7(2):231-9.
20. Bridoux F, Delbes S, Sirac C, et al. Atteintes rénales
des dysglobulinémies: avancées diagnostiques et thérapeutiques. Presse Med. 2012;41(3 Pt 1):276-89.
21. Karam S, Haidous M, Abou Dalle I, et al. Monoclonal gammopathy of renal significance: multidisciplinary approach to diagnosis and treatment. Crit Rev Oncol Hematol. 2023; 183:103926.
22. Fermand JP, Bridoux F, Kyle RA, et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013;122(22):3583-90.
23. Nie S, Wang M, Wan Q, et al. Kidney biopsy in patients with monoclonal gammopathy: a multicenter retrospective cohort study. Front Med (Lausanne). 2021; 8:687149.
24. Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009;20(9):2055-64.
25. Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006;81(5):693-703.
26. Sethi S, Rajkumar SV. Monoclonal gammopathy-associated proliferative glomerulonephritis. Mayo Clin Proc. 2013;88(12):1284-93.
27. Kourelis TV, Nasr SH, Dispenzieri A, et al. Outcomes of patients with renal monoclonal immunoglobulin deposition disease. Am J Hematol. 2016;91(10):1036-41.
28. Palladini G, Merlini G. How I treat AL amyloidosis. Blood. 2022;139(19):2918-30.
29. Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol. 2011;8(1):43-51.
30. Menè P, De Alexandris L, Moioli A, Raffa S, Stoppacciaro
A. Monoclonal gammopathies of renal significance: renal biopsy and beyond. Cancers (Basel). 2020;12(7):1741.
31. Fermand JP, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood.2018;132(14):1478-85.
32. Gozzetti A, Guarnieri A, Zamagni E, et al. Monoclonal gammopathy of renal significance (MGRS): real-world data on outcomes and prognostic factors. Am J Hematol. 2022;97(7):877-84.
33. Yadla M, Shankar M. Unraveling monoclonal gammopathy of renal significance: a mini review on kidney complications and clinical insights. Front Nephrol. 2024; 4:1439288.
34. Bridoux F, Leung N, Hutchison CA, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int. 2015;87(4):698-711.
35. Jiménez-Zepeda VH. Multiple myeloma in Latin America: Are we moving at the same pace as other regions? Rev Colomb Cancerol. 2023;27(2):191-3.doi:10.35509/01239015.1616.
Downloads
Published
Data Availability Statement
The datasets generated during this study are available from the corresponding author upon reasonable request via email
